Cocrystal Pharma Files To Start Human Trial For Protease Inhibitor In COVID-19

by Vandana Singh, Benzinga Editor

November 1, 2021 7:24 PM | 1 min read |

Cocrystal Pharma Inc COCP has submitted a pre-Investigational New Drug (IND) briefing package to the FDA for its broad-spectrum protease inhibitor CDI-45205 in COVID-19.
FDA's response is expected to provide greater clarity and guidance on designing Phase 1 and Phase 2 trials for CDI-45205.
Related Link: Cocrystal Pharma's Preclinical Protease Inhibitor Effective Against Original, Two Variant COVID-19 Strains.
CDI-45205 is among protease inhibitors obtained under an exclusive license agreement with Kansas State University Research Foundation (KSURF) in 2020.
CDI-45205 and several analogs showed potent in vitro activity against the variants, surpassing the activity observed with the original Wuhan strain.
Related content: Benzinga's Full FDA Calendar.
Price Action: COCP shares are up 5.92% at $0.95 on Monday.